New results show Eli Lilly (LLY) and Company’s Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic ...

Real-world evidence (RWE) leader, Target RWE, announced updates from its longitudinal dermatology study of more than 7,000 enrolled patients with two poster presentations on patients with Hidradenitis ...

Data demonstrated favorable safety and local tolerability of ZORYVE® (roflumilast) cream 0.15% in adults and children with atopic dermatitis (AD) with prior inadequate response, intolerance, and ...

ORLANDO, Fla., March 7, 2025 /PRNewswire/ -- The 2025 American Academy of Dermatology Annual Meeting will take place March 7-11 in Orlando. The meeting will ...

Contrary to some commonly held beliefs, current research shows that cutting out certain foods makes little difference in ...

Dupilumab rapidly treated and maintained improvements in lichenification, a type of skin thickening from repetitive ...

Sandra Koch, DVM, MS, DACVD, talks about the 4 reaction patterns associated with feline atopic skin syndrome, commonly known as environmental allergies or atopic dermatitis ...

High-parameter flow cytometry of peripheral blood mononuclear cells enabled physicians to treat recalcitrant erythroderma in ...

Upadacitinib is potentially safe and effective for patients with moderate to severe atopic dermatitis, irrespective of ...

Evelo Biosciences, Inc. (NASDAQ:EVLO – Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors bought 1,885 put options on the company. This is an increase ...

Aldeyra's reproxalap faced an FDA setback but showed positive trial results, leading to a resubmitted NDA. Click here to find ...

A new survey commissioned by Leo Pharma confirms that there’s plenty of room in the market for its chronic hand eczema ...